Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Amyloid Precursor Protein Linked to Alzheimer's Disease Mitochondrial Damage

By LabMedica International staff writers
Posted on 19 Jul 2010
Mitochondrial dysfunction in neurons, which typifies Alzheimer's disease, may be at least partially due to the interaction of a mitochondrial protein with amyloid precursor protein (APP).

A paper published in the June 2010 issue of the European Journal of Neuroscience described the discovery of the link between AAP and the mitochondrial protein NIPSNAP1 (4-nitrophenylphosphatase domain and non-neuronal SNAP25-like protein homolog 1).

First author Dr. More...
Hemachand Tummala, assistant professor of pharmaceutical sciences at South Dakota State University (Brookings, USA), explained, "In Alzheimer's disease, there is a protein involved called APP, amyloid precursor protein. If this protein is mutated, it causes early onset Alzheimer's disease. We do not know exactly what this protein does. One thing is very well documented in Alzheimer's disease; mitochondria in a cell are damaged. They lose their function. This happens long before the appearance of symptoms. So there is a theory that mitochondria play a big role in the disease progression.”

The authors reported that the interaction between APP and NIPSNAP1 was confirmed both in transiently transfected COS7 cells and in the mouse brain, where NIPSNAP1 is expressed at a high level. They demonstrated that NIPSNAP1 was targeted to the mitochondria via its N-terminal targeting sequence, and interacted with mitochondrial chaperone translocase of the outer membrane. Mitochondrial localization of NIPSNAP1 appeared to be critical for its interaction with APP, and overexpression of APP appeared to disrupt NIPSNAP1 mitochondrial localization.

"This work is still at the preliminary stages. If everything goes well, if we establish the link, this may in the future become a new therapeutic target,” said Dr. Tummala. "Our hypothesis is that mitochondria are damaged long before the appearance of symptoms. If you could stop that mitochondrial damage, it may slow down neuronal death and halt the disease progression. But that would be far in the future, not now.”

Related Links:
South Dakota State University






Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.